TrialSite has reported on a few different study results indicating that Roche’s Actemra (tocilizumab), an IL-6 inhibitor, doesn’t help to lower the death rate for hospitalized patients infected with severe to critical COVID-19. Now study results, recently published in...
India Approves Itolizumab & Tocilizumab for COVID-19: Controversy Commences over the Evidence while Demand Soars
200 mg vial Tocilizumab—15,000 Rs ($200.20)
400 mg vial Tocilizumab—30,000 Rs ($400.39)
Full Itolizumab Treatment—40,000 rupees
Great Plains Health Systems Investigate Treatment Options for COVID-19 Patients: Ivermectin Study Planned
Sanford Health and Essentia Health exemplify rock solid American Midwestern-Great Plains health systems on the front lines of the COVID-19 pandemic. Both health systems have embraced investigational therapies to treat a previously unknown, novel coronavirus as...
Genentech (Roche) Collaborates with BARDA to Launch Actemra Clinical Trial for Adult Patients with Severe COVID-19 Pneumonia
Genentech (Roche) plans a Phase III clinical trial to assess its marketed drug Actemra (tocilizumab) as a treatment for severe cases of COVID-19 in adults. In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), the prominent company...